Brian Adams, J.D., is the Chief Legal Officer at Kymera Therapeutics Inc., a clinical-stage biopharmaceutical company revolutionizing protein degradation therapies to treat diseases previously considered undruggable. In this role, Brian oversees all legal functions, including corporate governance, intellectual property strategy, regulatory affairs, mergers and acquisitions, and strategic partnerships. His leadership ensures Kymera's compliance with complex biotech regulations while supporting the company's aggressive pipeline advancement and business development initiatives. With more than 20 years of experience in life sciences law, Brian joined Kymera in 2021 from bluebird bio, where he served as General Counsel and led legal operations through pivotal clinical trials, FDA interactions, and capital raises exceeding $1 billion. Previously, he was a partner at WilmerHale, focusing on biotech M&A, venture financings, and licensing deals, and held roles at Third Rock Ventures advising on portfolio company formations and investments. Brian earned his J.D. from Harvard Law School and his B.A. from Stanford University. Brian's achievements include guiding numerous high-stakes transactions, such as Kymera's collaborations with Sanofi and Vertex Pharmaceuticals, its Nasdaq IPO, and follow-on offerings that fueled platform expansion. His strategic foresight has been key to mitigating risks in novel therapeutic modalities, earning him recognition as a top in-house counsel in the biotech sector.